Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular (IM) adminis...
Saved in:
| Published in | PLoS medicine Vol. 15; no. 11; p. e1002690 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
08.11.2018
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular (IM) administration, which delivers prolonged plasma exposure to the drug after IM injection. HIV Prevention Trials Network study 077 (HPTN 077) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States.
HPTN 077 was a double-blind, placebo-controlled phase 2a trial. Healthy individuals age 18-65 years at low HIV risk were randomized (3:1) to receive CAB or placebo (PBO). In the initial oral phase, participants received 1 daily oral tablet (CAB or PBO) for 4 weeks. Those without safety concerns in the oral phase continued and received injections in the injection phase (Cohort 1: 3 injections of CAB LA 800 mg or 0.9% saline as PBO IM every 12 weeks for 3 injection cycles; Cohort 2: CAB LA 600 mg or PBO IM for 5 injection cycles; the first 2 injections in Cohort 2 were separated by 4 weeks, the rest by 8 weeks). The primary analysis included weeks 5 to 41 of study participation, encompassing the injection phase. The cohorts were enrolled sequentially. Primary outcomes were safety and tolerability. Secondary outcomes included pharmacokinetics and events occurring during the oral and injection phases. Between February 9, 2015, and May 27, 2016, the study screened 443 individuals and enrolled 110 participants in Cohort 1 and 89 eligible participants in Cohort 2. Participant population characteristics were as follows: 66% female at birth; median age 31 years; 27% non-Hispanic white, 41% non-Hispanic black, 24% Hispanic/Latino, 3% Asian, and 6% mixed/other; and 6 transgender men and 1 transgender woman. Twenty-two (11%) participants discontinued the oral study product; 6 of these were for clinical or laboratory adverse events (AEs). Of those who received at least 1 CAB LA injection, 80% of Cohort 1 and 92% of Cohort 2 participants completed all injections; injection course completion rates were not different from those in the PBO arm. Injection site reactions (ISRs) were common (92% of Cohort 1 and 88% of Cohort 2 participants who received CAB LA reported any ISR). ISRs were mostly Grade 1 (mild) to Grade 2 (moderate), and 1 ISR event (Cohort 1) led to product discontinuation. Grade 2 or higher ISRs were the only AEs reported more commonly among CAB LA recipients than PBO recipients. Two Grade 3 (severe) ISRs occurred in CAB recipients, 1 in each cohort, but did not lead to product discontinuation in either case. Seven incident sexually transmitted infections were diagnosed in 6 participants. One HIV infection occurred in a participant 48 weeks after last injection of CAB LA: CAB was not detectable in plasma both at the time of first reactive HIV test and at the study visit 12 weeks prior to the first reactive test. Participants in Cohort 2 (unlike Cohort 1) consistently met prespecified pharmacokinetic targets of at least 95% of participants maintaining CAB trough concentrations above PA-IC90, and 80% maintaining trough concentrations above 4× PA-IC90. Study limitations include a modest sample size, a short course of injections, and a low-risk study population.
In this study, CAB LA was well tolerated at the doses and dosing intervals used. ISRs were common, but infrequently led to product discontinuation. CAB LA 600 mg every 8 weeks met pharmacokinetic targets for both male and female study participants. The safety and pharmacokinetic results observed support the further development of CAB LA, and efficacy studies of CAB LA for HIV treatment and prevention are in progress.
ClinicalTrials.gov Registry: ClinicalTrials.gov Trial number: NCT02178800. |
|---|---|
| AbstractList | Background Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular (IM) administration, which delivers prolonged plasma exposure to the drug after IM injection. HIV Prevention Trials Network study 077 (HPTN 077) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States. Methods and findings HPTN 077 was a double-blind, placebo-controlled phase 2a trial. Healthy individuals age 18–65 years at low HIV risk were randomized (3:1) to receive CAB or placebo (PBO). In the initial oral phase, participants received 1 daily oral tablet (CAB or PBO) for 4 weeks. Those without safety concerns in the oral phase continued and received injections in the injection phase (Cohort 1: 3 injections of CAB LA 800 mg or 0.9% saline as PBO IM every 12 weeks for 3 injection cycles; Cohort 2: CAB LA 600 mg or PBO IM for 5 injection cycles; the first 2 injections in Cohort 2 were separated by 4 weeks, the rest by 8 weeks). The primary analysis included weeks 5 to 41 of study participation, encompassing the injection phase. The cohorts were enrolled sequentially. Primary outcomes were safety and tolerability. Secondary outcomes included pharmacokinetics and events occurring during the oral and injection phases. Between February 9, 2015, and May 27, 2016, the study screened 443 individuals and enrolled 110 participants in Cohort 1 and 89 eligible participants in Cohort 2. Participant population characteristics were as follows: 66% female at birth; median age 31 years; 27% non-Hispanic white, 41% non-Hispanic black, 24% Hispanic/Latino, 3% Asian, and 6% mixed/other; and 6 transgender men and 1 transgender woman. Twenty-two (11%) participants discontinued the oral study product; 6 of these were for clinical or laboratory adverse events (AEs). Of those who received at least 1 CAB LA injection, 80% of Cohort 1 and 92% of Cohort 2 participants completed all injections; injection course completion rates were not different from those in the PBO arm. Injection site reactions (ISRs) were common (92% of Cohort 1 and 88% of Cohort 2 participants who received CAB LA reported any ISR). ISRs were mostly Grade 1 (mild) to Grade 2 (moderate), and 1 ISR event (Cohort 1) led to product discontinuation. Grade 2 or higher ISRs were the only AEs reported more commonly among CAB LA recipients than PBO recipients. Two Grade 3 (severe) ISRs occurred in CAB recipients, 1 in each cohort, but did not lead to product discontinuation in either case. Seven incident sexually transmitted infections were diagnosed in 6 participants. One HIV infection occurred in a participant 48 weeks after last injection of CAB LA: CAB was not detectable in plasma both at the time of first reactive HIV test and at the study visit 12 weeks prior to the first reactive test. Participants in Cohort 2 (unlike Cohort 1) consistently met prespecified pharmacokinetic targets of at least 95% of participants maintaining CAB trough concentrations above PA-IC90, and 80% maintaining trough concentrations above 4× PA-IC90. Study limitations include a modest sample size, a short course of injections, and a low-risk study population. Conclusions In this study, CAB LA was well tolerated at the doses and dosing intervals used. ISRs were common, but infrequently led to product discontinuation. CAB LA 600 mg every 8 weeks met pharmacokinetic targets for both male and female study participants. The safety and pharmacokinetic results observed support the further development of CAB LA, and efficacy studies of CAB LA for HIV treatment and prevention are in progress. Trial registration ClinicalTrials.gov Registry: ClinicalTrials.gov Trial number: NCT02178800. In a phase 2a trial, Raphael Landovitz and colleagues investigate the safety of injectable cabotegravir in HIV-uninfected people Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular (IM) administration, which delivers prolonged plasma exposure to the drug after IM injection. HIV Prevention Trials Network study 077 (HPTN 077) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States. HPTN 077 was a double-blind, placebo-controlled phase 2a trial. Healthy individuals age 18-65 years at low HIV risk were randomized (3:1) to receive CAB or placebo (PBO). In the initial oral phase, participants received 1 daily oral tablet (CAB or PBO) for 4 weeks. Those without safety concerns in the oral phase continued and received injections in the injection phase (Cohort 1: 3 injections of CAB LA 800 mg or 0.9% saline as PBO IM every 12 weeks for 3 injection cycles; Cohort 2: CAB LA 600 mg or PBO IM for 5 injection cycles; the first 2 injections in Cohort 2 were separated by 4 weeks, the rest by 8 weeks). The primary analysis included weeks 5 to 41 of study participation, encompassing the injection phase. The cohorts were enrolled sequentially. Primary outcomes were safety and tolerability. Secondary outcomes included pharmacokinetics and events occurring during the oral and injection phases. Between February 9, 2015, and May 27, 2016, the study screened 443 individuals and enrolled 110 participants in Cohort 1 and 89 eligible participants in Cohort 2. Participant population characteristics were as follows: 66% female at birth; median age 31 years; 27% non-Hispanic white, 41% non-Hispanic black, 24% Hispanic/Latino, 3% Asian, and 6% mixed/other; and 6 transgender men and 1 transgender woman. Twenty-two (11%) participants discontinued the oral study product; 6 of these were for clinical or laboratory adverse events (AEs). Of those who received at least 1 CAB LA injection, 80% of Cohort 1 and 92% of Cohort 2 participants completed all injections; injection course completion rates were not different from those in the PBO arm. Injection site reactions (ISRs) were common (92% of Cohort 1 and 88% of Cohort 2 participants who received CAB LA reported any ISR). ISRs were mostly Grade 1 (mild) to Grade 2 (moderate), and 1 ISR event (Cohort 1) led to product discontinuation. Grade 2 or higher ISRs were the only AEs reported more commonly among CAB LA recipients than PBO recipients. Two Grade 3 (severe) ISRs occurred in CAB recipients, 1 in each cohort, but did not lead to product discontinuation in either case. Seven incident sexually transmitted infections were diagnosed in 6 participants. One HIV infection occurred in a participant 48 weeks after last injection of CAB LA: CAB was not detectable in plasma both at the time of first reactive HIV test and at the study visit 12 weeks prior to the first reactive test. Participants in Cohort 2 (unlike Cohort 1) consistently met prespecified pharmacokinetic targets of at least 95% of participants maintaining CAB trough concentrations above PA-IC.sub.90, and 80% maintaining trough concentrations above 4x PA-IC.sub.90 . Study limitations include a modest sample size, a short course of injections, and a low-risk study population. In this study, CAB LA was well tolerated at the doses and dosing intervals used. ISRs were common, but infrequently led to product discontinuation. CAB LA 600 mg every 8 weeks met pharmacokinetic targets for both male and female study participants. The safety and pharmacokinetic results observed support the further development of CAB LA, and efficacy studies of CAB LA for HIV treatment and prevention are in progress. Background Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular (IM) administration, which delivers prolonged plasma exposure to the drug after IM injection. HIV Prevention Trials Network study 077 (HPTN 077) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States. Methods and findings HPTN 077 was a double-blind, placebo-controlled phase 2a trial. Healthy individuals age 18-65 years at low HIV risk were randomized (3:1) to receive CAB or placebo (PBO). In the initial oral phase, participants received 1 daily oral tablet (CAB or PBO) for 4 weeks. Those without safety concerns in the oral phase continued and received injections in the injection phase (Cohort 1: 3 injections of CAB LA 800 mg or 0.9% saline as PBO IM every 12 weeks for 3 injection cycles; Cohort 2: CAB LA 600 mg or PBO IM for 5 injection cycles; the first 2 injections in Cohort 2 were separated by 4 weeks, the rest by 8 weeks). The primary analysis included weeks 5 to 41 of study participation, encompassing the injection phase. The cohorts were enrolled sequentially. Primary outcomes were safety and tolerability. Secondary outcomes included pharmacokinetics and events occurring during the oral and injection phases. Between February 9, 2015, and May 27, 2016, the study screened 443 individuals and enrolled 110 participants in Cohort 1 and 89 eligible participants in Cohort 2. Participant population characteristics were as follows: 66% female at birth; median age 31 years; 27% non-Hispanic white, 41% non-Hispanic black, 24% Hispanic/Latino, 3% Asian, and 6% mixed/other; and 6 transgender men and 1 transgender woman. Twenty-two (11%) participants discontinued the oral study product; 6 of these were for clinical or laboratory adverse events (AEs). Of those who received at least 1 CAB LA injection, 80% of Cohort 1 and 92% of Cohort 2 participants completed all injections; injection course completion rates were not different from those in the PBO arm. Injection site reactions (ISRs) were common (92% of Cohort 1 and 88% of Cohort 2 participants who received CAB LA reported any ISR). ISRs were mostly Grade 1 (mild) to Grade 2 (moderate), and 1 ISR event (Cohort 1) led to product discontinuation. Grade 2 or higher ISRs were the only AEs reported more commonly among CAB LA recipients than PBO recipients. Two Grade 3 (severe) ISRs occurred in CAB recipients, 1 in each cohort, but did not lead to product discontinuation in either case. Seven incident sexually transmitted infections were diagnosed in 6 participants. One HIV infection occurred in a participant 48 weeks after last injection of CAB LA: CAB was not detectable in plasma both at the time of first reactive HIV test and at the study visit 12 weeks prior to the first reactive test. Participants in Cohort 2 (unlike Cohort 1) consistently met prespecified pharmacokinetic targets of at least 95% of participants maintaining CAB trough concentrations above PA-IC.sub.90, and 80% maintaining trough concentrations above 4x PA-IC.sub.90 . Study limitations include a modest sample size, a short course of injections, and a low-risk study population. Conclusions In this study, CAB LA was well tolerated at the doses and dosing intervals used. ISRs were common, but infrequently led to product discontinuation. CAB LA 600 mg every 8 weeks met pharmacokinetic targets for both male and female study participants. The safety and pharmacokinetic results observed support the further development of CAB LA, and efficacy studies of CAB LA for HIV treatment and prevention are in progress. Trial registration ClinicalTrials.gov Registry: ClinicalTrials.gov Trial number: NCT02178800. Background Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular (IM) administration, which delivers prolonged plasma exposure to the drug after IM injection. HIV Prevention Trials Network study 077 (HPTN 077) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States. Methods and findings HPTN 077 was a double-blind, placebo-controlled phase 2a trial. Healthy individuals age 18–65 years at low HIV risk were randomized (3:1) to receive CAB or placebo (PBO). In the initial oral phase, participants received 1 daily oral tablet (CAB or PBO) for 4 weeks. Those without safety concerns in the oral phase continued and received injections in the injection phase (Cohort 1: 3 injections of CAB LA 800 mg or 0.9% saline as PBO IM every 12 weeks for 3 injection cycles; Cohort 2: CAB LA 600 mg or PBO IM for 5 injection cycles; the first 2 injections in Cohort 2 were separated by 4 weeks, the rest by 8 weeks). The primary analysis included weeks 5 to 41 of study participation, encompassing the injection phase. The cohorts were enrolled sequentially. Primary outcomes were safety and tolerability. Secondary outcomes included pharmacokinetics and events occurring during the oral and injection phases. Between February 9, 2015, and May 27, 2016, the study screened 443 individuals and enrolled 110 participants in Cohort 1 and 89 eligible participants in Cohort 2. Participant population characteristics were as follows: 66% female at birth; median age 31 years; 27% non-Hispanic white, 41% non-Hispanic black, 24% Hispanic/Latino, 3% Asian, and 6% mixed/other; and 6 transgender men and 1 transgender woman. Twenty-two (11%) participants discontinued the oral study product; 6 of these were for clinical or laboratory adverse events (AEs). Of those who received at least 1 CAB LA injection, 80% of Cohort 1 and 92% of Cohort 2 participants completed all injections; injection course completion rates were not different from those in the PBO arm. Injection site reactions (ISRs) were common (92% of Cohort 1 and 88% of Cohort 2 participants who received CAB LA reported any ISR). ISRs were mostly Grade 1 (mild) to Grade 2 (moderate), and 1 ISR event (Cohort 1) led to product discontinuation. Grade 2 or higher ISRs were the only AEs reported more commonly among CAB LA recipients than PBO recipients. Two Grade 3 (severe) ISRs occurred in CAB recipients, 1 in each cohort, but did not lead to product discontinuation in either case. Seven incident sexually transmitted infections were diagnosed in 6 participants. One HIV infection occurred in a participant 48 weeks after last injection of CAB LA: CAB was not detectable in plasma both at the time of first reactive HIV test and at the study visit 12 weeks prior to the first reactive test. Participants in Cohort 2 (unlike Cohort 1) consistently met prespecified pharmacokinetic targets of at least 95% of participants maintaining CAB trough concentrations above PA-IC90, and 80% maintaining trough concentrations above 4× PA-IC90. Study limitations include a modest sample size, a short course of injections, and a low-risk study population. Conclusions In this study, CAB LA was well tolerated at the doses and dosing intervals used. ISRs were common, but infrequently led to product discontinuation. CAB LA 600 mg every 8 weeks met pharmacokinetic targets for both male and female study participants. The safety and pharmacokinetic results observed support the further development of CAB LA, and efficacy studies of CAB LA for HIV treatment and prevention are in progress. Trial registration ClinicalTrials.gov Registry: ClinicalTrials.gov Trial number: NCT02178800. Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular (IM) administration, which delivers prolonged plasma exposure to the drug after IM injection. HIV Prevention Trials Network study 077 (HPTN 077) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States. HPTN 077 was a double-blind, placebo-controlled phase 2a trial. Healthy individuals age 18-65 years at low HIV risk were randomized (3:1) to receive CAB or placebo (PBO). In the initial oral phase, participants received 1 daily oral tablet (CAB or PBO) for 4 weeks. Those without safety concerns in the oral phase continued and received injections in the injection phase (Cohort 1: 3 injections of CAB LA 800 mg or 0.9% saline as PBO IM every 12 weeks for 3 injection cycles; Cohort 2: CAB LA 600 mg or PBO IM for 5 injection cycles; the first 2 injections in Cohort 2 were separated by 4 weeks, the rest by 8 weeks). The primary analysis included weeks 5 to 41 of study participation, encompassing the injection phase. The cohorts were enrolled sequentially. Primary outcomes were safety and tolerability. Secondary outcomes included pharmacokinetics and events occurring during the oral and injection phases. Between February 9, 2015, and May 27, 2016, the study screened 443 individuals and enrolled 110 participants in Cohort 1 and 89 eligible participants in Cohort 2. Participant population characteristics were as follows: 66% female at birth; median age 31 years; 27% non-Hispanic white, 41% non-Hispanic black, 24% Hispanic/Latino, 3% Asian, and 6% mixed/other; and 6 transgender men and 1 transgender woman. Twenty-two (11%) participants discontinued the oral study product; 6 of these were for clinical or laboratory adverse events (AEs). Of those who received at least 1 CAB LA injection, 80% of Cohort 1 and 92% of Cohort 2 participants completed all injections; injection course completion rates were not different from those in the PBO arm. Injection site reactions (ISRs) were common (92% of Cohort 1 and 88% of Cohort 2 participants who received CAB LA reported any ISR). ISRs were mostly Grade 1 (mild) to Grade 2 (moderate), and 1 ISR event (Cohort 1) led to product discontinuation. Grade 2 or higher ISRs were the only AEs reported more commonly among CAB LA recipients than PBO recipients. Two Grade 3 (severe) ISRs occurred in CAB recipients, 1 in each cohort, but did not lead to product discontinuation in either case. Seven incident sexually transmitted infections were diagnosed in 6 participants. One HIV infection occurred in a participant 48 weeks after last injection of CAB LA: CAB was not detectable in plasma both at the time of first reactive HIV test and at the study visit 12 weeks prior to the first reactive test. Participants in Cohort 2 (unlike Cohort 1) consistently met prespecified pharmacokinetic targets of at least 95% of participants maintaining CAB trough concentrations above PA-IC90, and 80% maintaining trough concentrations above 4× PA-IC90. Study limitations include a modest sample size, a short course of injections, and a low-risk study population. In this study, CAB LA was well tolerated at the doses and dosing intervals used. ISRs were common, but infrequently led to product discontinuation. CAB LA 600 mg every 8 weeks met pharmacokinetic targets for both male and female study participants. The safety and pharmacokinetic results observed support the further development of CAB LA, and efficacy studies of CAB LA for HIV treatment and prevention are in progress. ClinicalTrials.gov Registry: ClinicalTrials.gov Trial number: NCT02178800. |
| Audience | Academic |
| Author | Landovitz, Raphael J Sugarman, Jeremy Zhang, Yinfeng Marzinke, Mark A Hendrix, Craig W Eshleman, Susan H Hosseinipour, Mina C Burns, David McCauley, Marybeth Panchia, Ravindre Cottle, Leslie Margolis, David Magnus, Manya Dawood, Halima Rinehart, Alex R Tolley, Elizabeth Richardson, Paul Li, Sue Chau, Gordon Cohen, Myron S Spreen, William R Liu, Albert Y Kofron, Ryan Grinsztejn, Beatriz Adeyeye, Adeola Eron, Joseph J |
| AuthorAffiliation | 8 Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa 7 UNC Project–Malawi, Lilongwe, Malawi 12 Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America 3 Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil 9 School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America 5 Bridge HIV, Population Health Division, San Francisco Department of Health, San Francisco, California, United States of America 1 UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States of America 4 Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa University of Southampton, UNITED KINGDOM 11 Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland, United States of America 10 FHI360, Durham, North Carolina, U |
| AuthorAffiliation_xml | – name: 1 UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States of America – name: 14 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America – name: 3 Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil – name: 9 School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America – name: 2 Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America – name: 11 Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland, United States of America – name: 10 FHI360, Durham, North Carolina, United States of America – name: 8 Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa – name: 12 Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America – name: 6 Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, United States of America – name: 13 ViiV Healthcare, Durham, North Carolina, United States of America – name: University of Southampton, UNITED KINGDOM – name: 5 Bridge HIV, Population Health Division, San Francisco Department of Health, San Francisco, California, United States of America – name: 7 UNC Project–Malawi, Lilongwe, Malawi – name: 4 Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa |
| Author_xml | – sequence: 1 givenname: Raphael J orcidid: 0000-0002-1442-714X surname: Landovitz fullname: Landovitz, Raphael J organization: UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States of America – sequence: 2 givenname: Sue surname: Li fullname: Li, Sue organization: Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America – sequence: 3 givenname: Beatriz orcidid: 0000-0003-3692-5155 surname: Grinsztejn fullname: Grinsztejn, Beatriz organization: Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil – sequence: 4 givenname: Halima surname: Dawood fullname: Dawood, Halima organization: Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa – sequence: 5 givenname: Albert Y orcidid: 0000-0003-0320-823X surname: Liu fullname: Liu, Albert Y organization: Bridge HIV, Population Health Division, San Francisco Department of Health, San Francisco, California, United States of America – sequence: 6 givenname: Manya surname: Magnus fullname: Magnus, Manya organization: Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, United States of America – sequence: 7 givenname: Mina C orcidid: 0000-0003-2174-313X surname: Hosseinipour fullname: Hosseinipour, Mina C organization: UNC Project-Malawi, Lilongwe, Malawi – sequence: 8 givenname: Ravindre surname: Panchia fullname: Panchia, Ravindre organization: Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa – sequence: 9 givenname: Leslie surname: Cottle fullname: Cottle, Leslie organization: Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America – sequence: 10 givenname: Gordon surname: Chau fullname: Chau, Gordon organization: Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America – sequence: 11 givenname: Paul surname: Richardson fullname: Richardson, Paul organization: School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America – sequence: 12 givenname: Mark A orcidid: 0000-0003-1670-8786 surname: Marzinke fullname: Marzinke, Mark A organization: School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America – sequence: 13 givenname: Craig W orcidid: 0000-0002-5696-8665 surname: Hendrix fullname: Hendrix, Craig W organization: School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America – sequence: 14 givenname: Susan H orcidid: 0000-0002-4587-791X surname: Eshleman fullname: Eshleman, Susan H organization: School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America – sequence: 15 givenname: Yinfeng surname: Zhang fullname: Zhang, Yinfeng organization: School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America – sequence: 16 givenname: Elizabeth orcidid: 0000-0002-9823-3675 surname: Tolley fullname: Tolley, Elizabeth organization: FHI360, Durham, North Carolina, United States of America – sequence: 17 givenname: Jeremy surname: Sugarman fullname: Sugarman, Jeremy organization: Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland, United States of America – sequence: 18 givenname: Ryan surname: Kofron fullname: Kofron, Ryan organization: UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States of America – sequence: 19 givenname: Adeola surname: Adeyeye fullname: Adeyeye, Adeola organization: Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America – sequence: 20 givenname: David surname: Burns fullname: Burns, David organization: Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America – sequence: 21 givenname: Alex R surname: Rinehart fullname: Rinehart, Alex R organization: ViiV Healthcare, Durham, North Carolina, United States of America – sequence: 22 givenname: David surname: Margolis fullname: Margolis, David organization: ViiV Healthcare, Durham, North Carolina, United States of America – sequence: 23 givenname: William R surname: Spreen fullname: Spreen, William R organization: ViiV Healthcare, Durham, North Carolina, United States of America – sequence: 24 givenname: Myron S surname: Cohen fullname: Cohen, Myron S organization: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America – sequence: 25 givenname: Marybeth surname: McCauley fullname: McCauley, Marybeth organization: FHI360, Durham, North Carolina, United States of America – sequence: 26 givenname: Joseph J orcidid: 0000-0002-4938-0644 surname: Eron fullname: Eron, Joseph J organization: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30408115$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVk21rFDEQxxep2Af9BqILgiC4Z5Ld7ENfCKWoPSit2Nq3IZvM7uWaS85kt1o_kp_SOXstPaig5MVmJ7_5z2Qms5tsOe8gSZ5TMqF5Rd_N_RictJPlAvSEEsLKhjxKdigvmoyWVbl1b7-d7MY4R6YhDXmSbOekIDWlfCf5dSY7GK7fpoO3EGRrrFn9SafT5UyGhVT-0jgYjIqp71LrXZ9JNRjXp8bNQQ2ytZAq2foB-iCvTEA7Yt-zYOJlejS9yEZnXIckaDzS5sroUdq4nx59Pj9JSVVhtFWsCCmTacDIfmF-Iqy8G4K3FrdDMNI-TR536AjP1t-95OvHD-eHR9nx6afp4cFxpuqaDhm0JS27pi1ZzQpd0oYBV7rrZAVFS2hBCg5FB1pxLjmjNS2hyTlQyrpW57zJ95KXN7pL66NYlzkKxjhjJa3LHInpDaG9nItlMAsZroWXRvwx-NALGbBkFkSdE51XraoU0UWXs5bxpmhV3ciqKOqOo9b7dbSxxU4qwEtLuyG6eeLMTPT-SpSM4V0YCrxaCwT_bYQ4_CXlNdVLzAob4lFMLUxU4oCX-BpwrZLJHqB6cPg0sPXQGTRv8JMHeFwaFkY96PBmw2HVY_gx9HKMUUzPvvwHe_Lv7OnFJvv6HjsDaYdZ9HYcjHdxEyxuQBV8jAG6u65QIlYzeFtpsZpBsZ5BdHtxv6N3TrdDl_8GbHQuBQ |
| CitedBy_id | crossref_primary_10_1111_bcp_14980 crossref_primary_10_1111_hiv_13451 crossref_primary_10_1128_aac_00781_23 crossref_primary_10_1128_aac_00053_23 crossref_primary_10_1021_acsptsci_0c00181 crossref_primary_10_25005_2074_0581_2023_25_1_22_35 crossref_primary_10_1038_s41467_023_36330_5 crossref_primary_10_1089_aid_2021_0127 crossref_primary_10_1080_17425255_2020_1752662 crossref_primary_10_1093_cid_ciz439 crossref_primary_10_1007_s40265_020_01379_9 crossref_primary_10_1093_infdis_jiaa296 crossref_primary_10_1002_jia2_25355 crossref_primary_10_1002_puh2_182 crossref_primary_10_1097_QAI_0000000000002409 crossref_primary_10_1186_s12981_022_00435_6 crossref_primary_10_1007_s40265_023_01963_9 crossref_primary_10_1097_ACI_0000000000000545 crossref_primary_10_1016_j_jve_2021_100030 crossref_primary_10_1016_j_pop_2021_02_004 crossref_primary_10_1089_aid_2020_0126 crossref_primary_10_2217_fvl_2019_0077 crossref_primary_10_1007_s40265_022_01791_3 crossref_primary_10_1128_aac_02057_21 crossref_primary_10_35772_ghm_2019_01003 crossref_primary_10_1002_jia2_25626 crossref_primary_10_1093_infdis_jiab152 crossref_primary_10_1097_COH_0000000000000602 crossref_primary_10_1097_COH_0000000000000723 crossref_primary_10_1016_S2352_3018_21_00153_3 crossref_primary_10_1111_bcp_15410 crossref_primary_10_3390_pharmaceutics11070315 crossref_primary_10_1208_s12248_022_00771_5 crossref_primary_10_1007_s10461_022_03816_0 crossref_primary_10_1021_acs_jmedchem_1c01118 crossref_primary_10_1186_s12981_023_00528_w crossref_primary_10_1093_infdis_jiaa552 crossref_primary_10_3390_polym13152450 crossref_primary_10_1093_infdis_jiaa555 crossref_primary_10_1080_14740338_2020_1764531 crossref_primary_10_22237_crp_1640995440 crossref_primary_10_1007_s10903_022_01412_x crossref_primary_10_1016_S2352_3018_21_00071_0 crossref_primary_10_1097_COH_0000000000000708 crossref_primary_10_3389_frph_2022_1081049 crossref_primary_10_1155_2021_6682932 crossref_primary_10_1016_j_jve_2020_100026 crossref_primary_10_1016_j_jcv_2021_105032 crossref_primary_10_1016_j_jddst_2023_104590 crossref_primary_10_3389_fgene_2022_940661 crossref_primary_10_1080_14656566_2020_1843635 crossref_primary_10_1089_apc_2023_0109 crossref_primary_10_1007_s10461_017_1972_6 crossref_primary_10_1016_j_eclinm_2020_100303 crossref_primary_10_1186_s12936_019_2921_9 crossref_primary_10_3390_pharmaceutics14081588 crossref_primary_10_1016_S2352_3018_19_30238_3 crossref_primary_10_1007_s40265_020_01313_z crossref_primary_10_1089_apc_2024_0076 crossref_primary_10_1002_rmv_2460 crossref_primary_10_1038_s41563_020_0674_z crossref_primary_10_1080_14787210_2024_2334054 crossref_primary_10_1111_bcp_15477 crossref_primary_10_1177_00185787211029546 crossref_primary_10_1002_jia2_25438 crossref_primary_10_1093_infdis_jiaa095 crossref_primary_10_1097_COH_0000000000000597 crossref_primary_10_1002_jms_4506 crossref_primary_10_2196_46767 crossref_primary_10_1007_s10876_022_02261_2 crossref_primary_10_1097_COH_0000000000000598 crossref_primary_10_1007_s11908_022_00780_7 crossref_primary_10_1089_apc_2019_0189 crossref_primary_10_1016_j_jconrel_2020_11_030 crossref_primary_10_1128_aac_01475_23 crossref_primary_10_1016_S2352_3018_20_30106_5 crossref_primary_10_1007_s40267_021_00847_w crossref_primary_10_1016_j_clinbiochem_2019_12_005 crossref_primary_10_1093_ofid_ofz365 crossref_primary_10_1021_acs_biochem_1c00157 crossref_primary_10_2174_1570162X18666200824104140 crossref_primary_10_1002_adtp_202000163 crossref_primary_10_1016_j_lanwpc_2022_100603 crossref_primary_10_1097_QAD_0000000000003887 crossref_primary_10_1097_QAD_0000000000003644 crossref_primary_10_1007_s10461_020_02808_2 crossref_primary_10_1089_apc_2021_0222 crossref_primary_10_1007_s11095_023_03470_8 crossref_primary_10_1016_S0140_6736_21_00570_5 crossref_primary_10_1177_23259582211009011 crossref_primary_10_1016_j_jconrel_2019_05_037 crossref_primary_10_3390_ph12020062 crossref_primary_10_1056_NEJMoa2101016 crossref_primary_10_3389_fphar_2021_664875 crossref_primary_10_1093_infdis_jiac415 crossref_primary_10_1016_S2352_3018_20_30165_X crossref_primary_10_1186_s12879_022_07572_3 crossref_primary_10_1371_journal_pgph_0000434 crossref_primary_10_3390_pharmaceutics15051487 crossref_primary_10_1016_S2352_3018_23_00200_X crossref_primary_10_1038_s41577_020_0274_9 crossref_primary_10_1097_COH_0000000000000733 crossref_primary_10_1097_QAD_0000000000003494 crossref_primary_10_1002_adfm_202106999 crossref_primary_10_1111_hiv_13663 crossref_primary_10_1186_s12879_020_05399_4 crossref_primary_10_1111_hiv_13262 crossref_primary_10_1016_S0140_6736_22_00538_4 crossref_primary_10_1093_ofid_ofab658 crossref_primary_10_1002_jia2_25963 crossref_primary_10_1136_bmjopen_2023_083837 crossref_primary_10_3389_fimmu_2022_1055042 crossref_primary_10_1097_QAD_0000000000003789 crossref_primary_10_15406_jhvrv_2019_07_00204 crossref_primary_10_1080_13543776_2020_1717470 crossref_primary_10_1016_j_ejmech_2024_116446 crossref_primary_10_1097_COH_0000000000000589 crossref_primary_10_3390_pharmaceutics14091761 crossref_primary_10_1016_j_tim_2019_02_009 |
| Cites_doi | 10.1056/NEJMoa1506273 10.1126/science.aap8131 10.1016/S0140-6736(15)00056-2 10.1128/AAC.00656-15 10.1097/COH.0000000000000002 10.1097/QAD.0000000000001343 10.1016/j.ejpb.2011.01.007 10.1016/S0140-6736(17)31917-7 10.1016/S1473-3099(14)70847-3 10.1056/NEJMoa1602046 10.1126/scitranslmed.3010298 10.1056/NEJMoa1011205 10.1056/NEJMoa1506110 10.1016/S1473-3099(15)00152-8 10.1097/QAD.0000000000000647 10.1016/S2352-3018(17)30068-1 10.1126/scitranslmed.3010297 10.1056/NEJMoa1110711 10.1097/GCO.0000000000000408 10.1056/NEJMoa1108524 10.1001/jamainternmed.2015.4683 10.1126/science.1248707 10.1097/01.AOG.0000437385.88715.4a |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2018 Public Library of Science This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: COPYRIGHT 2018 Public Library of Science – notice: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION IOV ISN ISR 3V. 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 5PM DOA CZK |
| DOI | 10.1371/journal.pmed.1002690 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Gale In Context: Opposing Viewpoints Gale In Context: Canada Gale In Context: Science ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) Directory of Open Access Journals PLoS Medicine |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) |
| DatabaseTitleList | Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 7X7 name: ProQuest_Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Safety, tolerability and pharmacokinetics of CAB LA in low-risk HIV-uninfected individuals |
| EISSN | 1549-1676 |
| Editor | Newell, Marie-Louise |
| Editor_xml | – sequence: 1 givenname: Marie-Louise surname: Newell fullname: Newell, Marie-Louise |
| ExternalDocumentID | 2252261863 oai_doaj_org_article_830d37bc7c0d4f32b2594bc89a7448f5 A564080805 10_1371_journal_pmed_1002690 30408115 |
| Genre | Multicenter Study Clinical Trial, Phase II Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | Brazil South Africa Malawi United States North Carolina Los Angeles California San Francisco California United States--US California Maryland Baltimore Maryland |
| GeographicLocations_xml | – name: South Africa – name: Malawi – name: United States – name: Brazil – name: California – name: San Francisco California – name: Baltimore Maryland – name: Los Angeles California – name: Maryland – name: North Carolina – name: United States--US |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: UM1 AI069423 – fundername: NIAID NIH HHS grantid: P30 AI050410 – fundername: NIAID NIH HHS grantid: UM1 AI068613 – fundername: NIAID NIH HHS grantid: P30 AI094189 – fundername: NIAID NIH HHS grantid: UM1 AI068619 – fundername: NIAID NIH HHS grantid: U01 AI069424 – fundername: NIAID NIH HHS grantid: UM1 AI069530 – fundername: NIAID NIH HHS grantid: UM1 AI068617 – fundername: ; grantid: UM1AI068613 – fundername: ; grantid: UM1AI068619 – fundername: ; grantid: UM1AI1068617 |
| GroupedDBID | --- 123 29O 2WC 3V. 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAWTL ABDBF ABUWG ACGFO ACIHN ACPRK ADBBV ADRAZ AEAQA AENEX AFKRA AFRAH AFXKF AHMBA AKRSQ ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS B0M BAWUL BCGST BCNDV BENPR BPHCQ BVXVI BWKFM CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EAP EAS EBD EBS ECM EIF EJD EMK EMOBN ESX F5P FPL FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO ICW IHR IHW INH INR IOF IOV IPNFZ IPO ISN ISR ITC KQ8 M1P M48 MK0 M~E NPM O5R O5S OK1 P2P PIMPY PQQKQ PROAC PSQYO PV9 RIG RNS RPM RZL SV3 TR2 TUS UKHRP WOQ WOW XSB YZZ ~8M AAYXX CITATION AFPKN 7TK 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 5PM AAPBV ABPTK CZK |
| ID | FETCH-LOGICAL-c881t-eb616f9b62824d6192e5cdffa7e4b014045e4fedc55a521816e935e112fbd3593 |
| IEDL.DBID | RPM |
| ISSN | 1549-1676 1549-1277 |
| IngestDate | Sun Jun 04 13:13:08 EDT 2023 Tue Oct 22 15:15:58 EDT 2024 Tue Sep 17 21:05:40 EDT 2024 Thu Oct 10 22:37:24 EDT 2024 Tue Nov 19 21:09:48 EST 2024 Thu Nov 14 21:15:37 EST 2024 Tue Nov 12 23:27:42 EST 2024 Thu Aug 01 19:32:20 EDT 2024 Thu Aug 01 20:36:47 EDT 2024 Thu Aug 01 19:26:52 EDT 2024 Tue Aug 20 22:12:22 EDT 2024 Thu Nov 21 20:57:58 EST 2024 Wed Oct 16 00:44:36 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Creative Commons CC0 public domain |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c881t-eb616f9b62824d6192e5cdffa7e4b014045e4fedc55a521816e935e112fbd3593 |
| Notes | RJL has received study medication, consulting fees and travel support from Gilead Sciences. He has received consulting fees and travel support from Merck, Inc. HD has received honoraria from Pfizer-South Africa, Novartis-South Africa, MSD-South Africa and Adcock Ingram for speaking engagements and has received travel support from Mylan-South Africa, Novartis-South Africa and Aspen-South Africa. AYL received research grants from NIH and has led studies in which study drug was donated by Gilead Sciences. DM and ARR are paid employees of ViiV Healthcare. WRS is a paid employee of ViiV Healthcare with stock in ViiV Healthcare and GlaxoSmithKline. CWH has research contracts with ViiV/GlaxoSmithKline and the NIH through Johns Hopkins and the University of Washington. MAM received grant support through the NIH, and received grant support through ViiV/GSK on work external to this study. JS is a member of Merck KGaA's Bioethics Advisory Panel and Stem Cell Research Oversight Committee; and he is a member of IQVIA's (formerly Quintiles) Ethics Advisory Panel. JJE is a consultant to Merck, Gilead Sciences, Janssen, and ViiV Healthcare; and he is an investigator on research contracts from ViiV Healthcare, Janssen, and Gilead Sciences. |
| ORCID | 0000-0002-9823-3675 0000-0002-4938-0644 0000-0002-5696-8665 0000-0002-4587-791X 0000-0003-2174-313X 0000-0003-0320-823X 0000-0002-1442-714X 0000-0003-3692-5155 0000-0003-1670-8786 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224042/ |
| PMID | 30408115 |
| PQID | 2252261863 |
| PQPubID | 1436338 |
| ParticipantIDs | plos_journals_2252261863 doaj_primary_oai_doaj_org_article_830d37bc7c0d4f32b2594bc89a7448f5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6224042 proquest_journals_2252261863 gale_infotracmisc_A564080805 gale_infotracgeneralonefile_A564080805 gale_infotracacademiconefile_A564080805 gale_incontextgauss_ISR_A564080805 gale_incontextgauss_ISN_A564080805 gale_incontextgauss_IOV_A564080805 gale_healthsolutions_A564080805 crossref_primary_10_1371_journal_pmed_1002690 pubmed_primary_30408115 |
| PublicationCentury | 2000 |
| PublicationDate | 20181108 |
| PublicationDateYYYYMMDD | 2018-11-08 |
| PublicationDate_xml | – month: 11 year: 2018 text: 20181108 day: 8 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PLoS medicine |
| PublicationTitleAlternate | PLoS Med |
| PublicationYear | 2018 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | AY Liu (ref7) 2016; 176 CD Andrews (ref20) 2015; 7 ref15 RM Grant (ref1) 2010; 363 GB Schivone (ref9) 2017; 29 J Radzio (ref19) 2015; 7 ref10 JM Baeten (ref28) 2016; 375 JM Molina (ref4) 2015; 373 ref17 (ref24) 2013; 122 MS Cohen (ref26) 2017; 358 WR Spreen (ref12) 2013; 8 S McCormack (ref5) 2016; 387 CD Andrews (ref18) 2014; 343 DA Margolis (ref13) 2015; 15 RM Grant (ref6) 2014; 14 ref23 CD Andrews (ref16) 2017; 31 ref25 A Nel (ref29) 2016; 375 RH Müller (ref11) 2011; 78 JM Baeten (ref2) 2012; 367 DA Margolis (ref14) 2017; 390 MC Thigpen (ref3) 2012; 367 M Gunawardana (ref27) 2015; 59 JE Haberer (ref8) 2015; 29 M Markowitz (ref21) 2017; 4 TF Babor (ref22) 2001 |
| References_xml | – volume: 373 start-page: 2237 issue: 23 year: 2015 ident: ref4 article-title: On-demand preexposure prophylaxis in men at high risk for HIV-1 infection publication-title: N Engl J Med doi: 10.1056/NEJMoa1506273 contributor: fullname: JM Molina – volume: 358 start-page: 46 issue: 6359 year: 2017 ident: ref26 article-title: Broadly neutralizing antibodies to prevent HIV-1 publication-title: Science doi: 10.1126/science.aap8131 contributor: fullname: MS Cohen – volume: 387 start-page: 53 issue: 10013 year: 2016 ident: ref5 article-title: Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(15)00056-2 contributor: fullname: S McCormack – volume: 59 start-page: 3913 issue: 7 year: 2015 ident: ref27 article-title: Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00656-15 contributor: fullname: M Gunawardana – volume: 8 start-page: 565 issue: 6 year: 2013 ident: ref12 article-title: Long-acting injectable antiretrovirals for HIV treatment and prevention publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0000000000000002 contributor: fullname: WR Spreen – volume: 31 start-page: 461 issue: 4 year: 2017 ident: ref16 article-title: Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251 publication-title: AIDS doi: 10.1097/QAD.0000000000001343 contributor: fullname: CD Andrews – volume: 78 start-page: 1 issue: 1 year: 2011 ident: ref11 article-title: State of the art of nanocrystals—special features, production, nanotoxicology aspects and intracellular delivery publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2011.01.007 contributor: fullname: RH Müller – volume: 390 start-page: 1499 issue: 10101 year: 2017 ident: ref14 article-title: Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(17)31917-7 contributor: fullname: DA Margolis – volume: 14 start-page: 820 issue: 9 year: 2014 ident: ref6 article-title: Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(14)70847-3 contributor: fullname: RM Grant – volume: 375 start-page: 2133 issue: 22 year: 2016 ident: ref29 article-title: Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women publication-title: N Engl J Med doi: 10.1056/NEJMoa1602046 contributor: fullname: A Nel – volume: 7 start-page: 270ra4 issue: 270 year: 2015 ident: ref20 article-title: A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3010298 contributor: fullname: CD Andrews – volume: 363 start-page: 2587 issue: 27 year: 2010 ident: ref1 article-title: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men publication-title: N Engl J Med doi: 10.1056/NEJMoa1011205 contributor: fullname: RM Grant – volume: 375 start-page: 2121 issue: 22 year: 2016 ident: ref28 article-title: Use of a vaginal ring containing dapivirine for HIV-1 prevention in women publication-title: N Engl J Med doi: 10.1056/NEJMoa1506110 contributor: fullname: JM Baeten – ident: ref25 – volume: 15 start-page: 1145 issue: 10 year: 2015 ident: ref13 article-title: Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(15)00152-8 contributor: fullname: DA Margolis – volume: 29 start-page: 1277 issue: 11 year: 2015 ident: ref8 article-title: Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm publication-title: AIDS doi: 10.1097/QAD.0000000000000647 contributor: fullname: JE Haberer – volume: 4 start-page: e331 issue: 8 year: 2017 ident: ref21 article-title: Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial publication-title: Lancet HIV doi: 10.1016/S2352-3018(17)30068-1 contributor: fullname: M Markowitz – ident: ref17 – ident: ref15 – volume: 7 start-page: 270ra5 issue: 270 year: 2015 ident: ref19 article-title: The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3010297 contributor: fullname: J Radzio – volume: 367 start-page: 423 issue: 5 year: 2012 ident: ref3 article-title: Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana publication-title: N Engl J Med doi: 10.1056/NEJMoa1110711 contributor: fullname: MC Thigpen – volume: 29 start-page: 443 issue: 6 year: 2017 ident: ref9 article-title: Contraceptive counseling for continuation and satisfaction publication-title: Curr Opin Obstet Gynecol doi: 10.1097/GCO.0000000000000408 contributor: fullname: GB Schivone – volume: 367 start-page: 399 issue: 5 year: 2012 ident: ref2 article-title: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women publication-title: N Engl J Med doi: 10.1056/NEJMoa1108524 contributor: fullname: JM Baeten – ident: ref23 – volume: 176 start-page: 75 issue: 1 year: 2016 ident: ref7 article-title: Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2015.4683 contributor: fullname: AY Liu – volume: 343 start-page: 1151 issue: 6175 year: 2014 ident: ref18 article-title: Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus publication-title: Science doi: 10.1126/science.1248707 contributor: fullname: CD Andrews – volume: 122 start-page: 1139 year: 2013 ident: ref24 article-title: ACOG Committee Opinion No 579: definition of term pregnancy publication-title: Obstet Gynecol doi: 10.1097/01.AOG.0000437385.88715.4a – ident: ref10 – year: 2001 ident: ref22 contributor: fullname: TF Babor |
| SSID | ssj0029090 |
| Score | 2.6318343 |
| Snippet | Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an... Background Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an... In a phase 2a trial, Raphael Landovitz and colleagues investigate the safety of injectable cabotegravir in HIV-uninfected people BACKGROUND:Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an... Background Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an... |
| SourceID | plos doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | e1002690 |
| SubjectTerms | Acquired immune deficiency syndrome Adolescent Adult Aged AIDS AIDS treatment Analysis Anti-HIV Agents - administration & dosage Anti-HIV Agents - adverse effects Anti-HIV Agents - blood Anti-HIV Agents - pharmacokinetics Antiretroviral drugs Biology and Life Sciences Brazil Cancer Clinical trials Delayed-Action Preparations Disease prevention Disease transmission Dosage Double-Blind Method Drug Administration Schedule Drug Monitoring Female Females Funding Health risks HIV HIV infections HIV Infections - diagnosis HIV Infections - prevention & control HIV Infections - transmission HIV Infections - virology Human immunodeficiency virus Humans Infections Infectious diseases Injection Injections, Intramuscular Integrase Malawi Male Males Medical research Medicine Medicine and Health Sciences Men Middle Aged Novels Pharmacokinetics Plasma physics Population characteristics Population studies Prevention Pyridones - administration & dosage Pyridones - adverse effects Pyridones - blood Pyridones - pharmacokinetics Randomization Research and analysis methods Risk Assessment Risk Factors Safety Safety and security measures Sexually transmitted diseases Software South Africa Supervision Tenofovir Transgender people Treatment Outcome United States Young Adult |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZQD4gL4r1dFrAQggthk_gZbgti1UWiIPahvUWJY5eKklRNC4KfxK9kxnGrBlViD9za5GujeMbjb5KZz4Q8Y8wo4N3A3IrERbyAhBVfEkYGbA1sv1AQl7HaYixH5_z9pbjc2uoLa8I6eeBu4A41iyumSqNMXHHH0hL4Oi-Nhr-BzMJ16qVxuk6mQqqVxf7pCuqPRUmqVGiaYyo5DDZ6NYfVxguQSozHW4uS1-7fROjBfNa0u-jn31WUW8vS8S1yM_BJetTdx21yzdZ3yPUP4Y35XfL7tHB2-fMlXTYzu-hEueFbUVd0HlSrvwIQxZpp4-isqScR9jrUEzqt8RkNtlZRA67iZSW-TxdwHGA_IixKp6OTi2hVdxVdtqLTTXtX-5qOPp2NaawUXA2v1VqaFhSWxqr5Nv0F4FAlP4OPfu-Qe-T8-N3Z21EU9meIjNbJMrKlTKTLSglpG68wE7PCVM6BgXnpdXuE5Q4GSIhCIJWQNmPCAsNzZcVExu6TQd3Udo_QlKmU29hIkRmupNTWaWZ05ZJKpFymQxKtDZTPOxmO3L-LU5C-dCOdo0HzYNAheYNW3GBRRNsfANfKg2vl_3KtIXmCPpB3HambUJAfCclj1OMExFOPQCGNGit1JsWqbfOTjxdXAJ2OrwL63AO9CCDXgMuZIrRQwBiiilcP-byHnHQa5ruABz0gBBfTO72H_r8e4zaH8A-EPdGSwS_Xc2L36Qfd9NjYgMF6oSEBGRLVmzg9I_XP1NMvXvFcIvHk6f7_sOpDcgNIr_b9pPqADJaLlX0ExHJZPvYx5A_u4XPE priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Zj9MwELagSIgXxL2FBSyE4IWwSXylvKAFseoiURB7qG9R4qNUlKQ0LQh-Er-SGcftblCF9q2JvyqSZzyHPfOZkKeMaQVxN0RuReIiXkDCioeEkQZZQ7RfKLDLWG0xksMT_n4sxmHDrQlllWub6A21qTXuke-B3kGkkGSSvZ5_j_DWKDxdDVdoXCZXkhRcOeizGp8lXIPY77EgC1mUpEqF1jmmkr0gqZdz8DmehlSiVT7nmjyD_8ZO9-azutkWhP5bS3nOOR3cINdDVEn3WzW4SS7Z6ha5-iGcm98mf44KZ5e_XtBlPbOLlpobnorK0Hngrv4KQKRsprWjs7qaRNjxUE3otMKdGmywohoUxpNL_Jgu4D3AfkZYmk6Hh6fRqmrruqyh002TV_OKDj8dj2isFHwNv9VYmhYUHKSpv01_AzjUys_gp79B5A45OXh3_HYYhVsaIp1lyTKypUykG5QSkjduMB-zQhvnQMy89Ow9wnIHEyREITCgkHbAhIU4z5WGiQG7S3pVXdkdQlOmUm5jLcVAcyVlZl3GdGZcYkTKZdon0VpA-bwl48j9iZyCJKad6RwFmgeB9skblOIGi1Ta_kW9mORhZeYZiw1TpVY6NtyxtISEkJc6Az2F1NWJPnmMOpC3fakbg5DvC8ljZOUExBOPQDqNCut1JsWqafLDj6cXAB2NLgL63AE9DyBXg8rpIjRSwBwil1cH-ayDnLRM5tuAux0gmBjdGd5B_V_PcZOfLUb453pNbB--1y6PjQwYeI0M0pA-UZ2F0xFSd6SafvG85xLDT57e__8nH5BrENRmvl802yW95WJlH0LguCwfeevwFyH3a3I priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1tb9MwELZGkRBfEO_rGGAhBF_IlMSvRUJoIKYOaQWxddq3KHHsUlGSrmmB8ZP4ldw5aURQkca3Jn7SSHdn311895iQp4wZBXE3RG5p5AKeQsKKm4SBAV1DtJ8qWJex2mIkh2P-_kycbZH1ma2NAKuNqR2eJzVezPZ-nF-8hgn_yp_aoKL1Q3tz8B-eUhQyvivkagy-EYu8jni7rxAPQv_VBXnJgkgq2TTT_etfOs7Kc_q3K3dvPiurTWHp39WVf7irg5vkRhNn0v3aMG6RLVvcJteOmp30O-TXcers8uIFXZYzu6jJuuEqLXI6b9isvwAQSZxp6eisLCYB9kAUEzot8NsNtlxRAybk6Sa-TRdwH2DfAyxWp8PD02BV1JVeNqfTtu2rekmHH09GNFQK3obvqiyNUwouMy-_Tn8CuKmen8FPf6bIXTI-eHfydhg05zYERutoGdhMRtINMgnpHM8xQ7PC5M6B4nnm-XyE5Q4EJEQqMMSQdsCEhcjPZTkTA3aP9IqysNuExkzF3IZGioHhSkptnWZG5y7KRcxl3CfBWkHJvKbnSPwenYK0ppZ0ggpNGoX2yRvUYotFcm1_o1xMkmauJpqFOVOZUSbMuWNxBikiz4wGy4Vk1ok-eYw2kNSdqu0SkewLyUPk6QTEE49Ago0CK3gm6aqqksMPp5cAHY8uA_rUAT1vQK4EkzNp01oBMkR2rw7yWQc5qbnNNwF3O0BYdExneBvtfy3jKgG3AIF8pCWDJ9dzYvPw_Xp6tDpg4Ec0JCZ9ojoTp6Ok7kgx_eyZ0CUGpDze-U8reECuQ9yrfUup3iW95WJlH0Jsucwe-eXiN6e4d3Y priority: 102 providerName: Scholars Portal |
| Title | Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30408115 https://www.proquest.com/docview/2252261863 https://pubmed.ncbi.nlm.nih.gov/PMC6224042 https://doaj.org/article/830d37bc7c0d4f32b2594bc89a7448f5 http://dx.doi.org/10.1371/journal.pmed.1002690 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZtBqUvY_dm6zIxxvYyN7F1c_bWlpZ0kCz0Rt6MLUupWWKHONnYftJ-5Y5kOdQjD2UEQmx9xkHn6Fzscz4h9IEQKSDuhsgt9rVHY0hYzUtCT4KsIdqPBdhlU20x4oMb-nXCJjuI1b0wtmhfJtlRPpsf5dmdra1czGW3rhPrjoen3PghGnR30S643zpFd1lWv2cfrBjqMc8PhHD9ckT4XSeeowU4Gss9CqnhPtqDjB4co9kY955rsgz-GzvdWsyKclsQ-m8t5T3ndP4EPXZRJT6u_v1TtKPyZ2hv6N6bP0d_rmKtVr8-41UxU8uKmhuO4jzFC8dd_R2AhrIZFxrPinzqmY6HfIqz3DypMQ1WWILCWHKJH9kSzgPsp2dK0_Hg4tZb51Vdl0pxtmnyKr_gwfh6hHtCwN3MvUqFgxiDg0yLefYbwK5WfgY_7Q4iL9DN-dn16cBzuzR4Mgz9lacS7nPdTzgkbzQ1-ZhiMtUaxEwTy97DFNUwQYzFzAQUXPUJUxDn6SQlrE9eolZe5OoA4YCIgKqe5KwvqeA8VDokMky1n7KA8qCNvFpA0aIi44jsGzkBSUw105GRbeRk20YnRoobrKHStieK5TRyChWFpJcSkUgheynVJEggIaSJDEFPIXXVrI3eGR2Iqr7UjUGIjhkHtYEPIN5bhKHTyE29zjRel2V08e32AaCr0UNAlw3QJwfSBaicjF0jBcyh4fJqID82kNOKyXwb8LABBBMjG8MHRv_rOS4jcAIQtvshJ3BlvSa2D7-qlsdGBvViayPRWDgNITVHwAxY3nO37F__95Vv0D7Eu6FtJQ0PUWu1XKu3EFOukg5YkonooEcnZ6PxZcc-mYHvIQ071rr8BfnHeKg |
| link.rule.ids | 230,314,727,780,784,864,885,2102,2221,12056,21388,24318,27924,27925,31719,33744,43310,43805,53791,53793,73745,74302 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELegk4AXxPcKg1kIwQthSfyV8oI2tKmFrUxbN-0tShy7VJSkNC0I_iT-Su4SNyyoQntL4l9kyXc-39l3PxPygjGtwO8Gzy0JrMcTCFjxkNDTIGvw9hMFdhmzLYayf8Y_XIgLt-FWurTKlU2sDHVWaNwj3wG9A08hiCR7N_vm4a1ReLrqrtC4TjaQOV10yMbe_vD4pAm5en61y4I8ZF4QKuWK55gKdpys3sxg1amISCXa5UuLU8Xh31jqzmxalOvc0H-zKS8tTwd3yG3nV9LdWhHukmsmv0duHLmT8_vk92lizeLna7oopmZek3PDW5JndObYq78AEEmbaWHptMjHHtY85GM6yXGvBkusqAaVqeglvk_m8B1gPzxMTqf9wbm3zOvMLpPRSVPmVb6l_ePRkPpKQW_YV2lomFBYIrPi6-QXgF22_BQeqztEHpCzg_3R-77n7mnwdBQFC8-kMpC2l0oI33iGEZkROrMWBM3Tir9HGG5hgIRIBLoU0vSYMODp2TRjoscekk5e5GaT0JCpkBtfS9HTXEkZGRsxHWU2yETIZdgl3kpA8aym44irMzkFYUw90jEKNHYC7ZI9lGKDRTLt6kMxH8dubsYR8zOmUq20n3HLwhRCQp7qCDQVglcrumQbdSCuK1MbkxDvCsl95OUExPMKgYQaOWbsjJNlWcaDT-dXAJ0OrwI6aYFeOZAtQOV04kopYAyRzauFfNlCjmsu83XArRYQjIxuNW-i_q_GuIz_Tkf4czUn1jc_qqdHIwMG60YEgUiXqNbEaQmp3ZJPPlfM5xIdUB4-_n-X2-Rmf3R0GB8Ohh-fkFvg4kZV9Wi0RTqL-dI8BTdykT5ztuIPeQhvyA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLagkyZeJu4rDGYhBC-EJvEt5QVtsKrlUqrdtLcocexSUZLStCD4SfxKzkncsqAK7a2JvyqSz_G52Od8JuQpY1pB3A2RWxJYjyeQsOIhoadB1hDtJwrsMlZbDGX_jL-7EBeu_ql0ZZUrm1gZ6qzQuEfeAb2DSCGIJOtYVxYxett7Pfvm4Q1SeNLqrtO4TrbAK_phi2wdHg1Hx-v0q-tXOy7ISeYFoVKukY6poOPk9nIGHqgiJZVooy85qorPf221W7NpUW4KSf-trLzkqno3yY6LMelBrRS3yDWT3ybbH90p-h3y-ySxZvHzBV0UUzOvibrhKckzOnNM1l8AiATOtLB0WuRjD_sf8jGd5Lhvg-1WVIP6VFQT3ydzeA-wHx4WqtP-4Nxb5nWVl8noZN3yVb6i_dHpkPpKwdfwW6WhYULBXWbF18kvALvK-Sn8rO4TuUvOekenb_qeu7PB01EULDyTykDabiohleMZZmdG6MxaEDpPKy4fYbiFCRIiERheSNNlwkDUZ9OMiS67R1p5kZtdQkOmQm58LUVXcyVlZGzEdJTZIBMhl2GbeCsBxbOamiOuzucUpDT1TMco0NgJtE0OUYprLBJrVy-K-Th26zSOmJ8xlWql_YxbFqaQHvJUR6C1kMha0Sb7qANx3aW6Ng_xgZDcR45OQDypEEiukaOajpNlWcaDT-dXAJ0MrwI6boCeO5AtQOV04toqYA6R2auBfNZAjmte803AvQYQDI5uDO-i_q_muIz_Lk3452pNbB6-Xy-PtQwY-JAIkpI2UY2F0xBScySffK5Y0CUGozx88P9P7pNtMBPxh8Hw_UNyA6LdqGokjfZIazFfmkcQUS7Sx85U_AHtKnP1 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety%2C+tolerability%2C+and+pharmacokinetics+of+long-acting+injectable+cabotegravir+in+low-risk+HIV-uninfected+individuals%3A+HPTN+077%2C+a+phase+2a+randomized+controlled+trial&rft.jtitle=PLoS+medicine&rft.au=Landovitz%2C+Raphael+J.&rft.au=Li%2C+Sue&rft.au=Grinsztejn%2C+Beatriz&rft.au=Dawood%2C+Halima&rft.date=2018-11-08&rft.issn=1549-1676&rft.eissn=1549-1676&rft.volume=15&rft.issue=11&rft.spage=e1002690&rft_id=info:doi/10.1371%2Fjournal.pmed.1002690&rft.externalDBID=n%2Fa&rft.externalDocID=10_1371_journal_pmed_1002690 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1549-1676&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1549-1676&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1549-1676&client=summon |